Thirty years of the human immunodeficiency virus epidemic and beyond. by Younai, Fariba S
UCLA
UCLA Previously Published Works
Title
Thirty years of the human immunodeficiency virus epidemic and beyond.
Permalink
https://escholarship.org/uc/item/2kc75750
Journal
International journal of oral science, 5(4)
ISSN
1674-2818
Author
Younai, Fariba S
Publication Date
2013-12-01
DOI
10.1038/ijos.2013.76
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
REVIEW
Thirty years of the human immunodeficiency virus
epidemic and beyond
Fariba S Younai
After more than 30 years of battling a global epidemic, the prospect of eliminating human immunodeficiency virus (HIV) as the most
challenging infectious disease of the modern era is within our reach. Major scientific discoveries about the virus responsible for this
immunodeficiency disease state, including its pathogenesis, transmission patterns and clinical course, have led to the development of
potent antiretroviral drugs that offer great hopes in HIV treatment and prevention. Although these agents and many others still in
development and testing are capable of effectively suppressing viral replication and survival, themedicalmanagement of HIV infection
at the individual and the population levels remains challenging. Timely initiation of antiretroviral drugs, adherence to the appropriate
therapeutic regimens, effective use of these agents in the pre and post-exposure prophylaxis contexts, treatment of comorbid
conditions and addressing social and psychological factors involved in the care of individuals continue to be important considerations.
International Journal of Oral Science (2013) 5, 191–199; doi:10.1038/ijos.2013.76; published online 18 October 2013
Keywords: human immunodeficiency virus; treatment; prevention; global impact; antiretrovirals; epidemiology
BACKGROUND
In 1981, the first cases of a deadly new infectious disease occurring in
previously healthy gay men and manifested by Pneumocystis pneumonia
and Kaposi’s sarcoma, were reported in New York and Los Angeles.1
Shortly after these initial reports, news of infection among a small num-
ber of migrants from the Caribbean island of Haiti as well as individuals
with a history of hemophilia and injection drug use started to surface.2–6
The condition was given a number of names in the American and the
European popular press (including the gay-related immune deficiency)
and in September 1982, the US Centers for Disease Control began
referring to it as ‘acquired immune deficiency syndrome’ or ‘AIDS’.7
In 1983, as cases of AIDS started to manifest among female sexual
partners of infected men,8–9 the causative agent was identified and later
named ‘human immunodeficiency virus type 1’ or ‘HIV-1’;10–12 in 1985,
the enzyme immunoassay test for HIV-1 antibodies became available;13
and in 1986, HIV-2 was isolated from patients diagnosed with AIDS in
West Africa.14 Since its original description 32 years ago, HIV has
become one of the most significant infectious diseases worldwide and
has challenged public health systems in every country affected by the
epidemic. This article provides an overview of the HIV disease epidemic
including its global impact, viral pathogenesis, important clinical fea-
tures and many of the current medical management and prevention
strategies employed. Although comprehensive in nature, portions of this
review focuses on USA data to help highlight specific issues.
THE ORIGIN OF HIV
HIV-1 is closely related to the simian immunodeficiency viruses SIVcpz
from the Troglodytes chimpanzees and the SIVgor found in the Western
lowland gorillas, whereas HIV-2 is similar to the SIVsm from the sooty
mangabey monkeys; these primates inhabit Cameroon and Congo in
Central Africa and in Ivory Coast in Western Africa, respectively.15–17
Although it is now widely accepted that HIV originated from cross-
species transmission of these simian immunodeficiency viruses from
the primates to humans, the causes of its original spread among human
populations is still under much debate. It has been postulated that a
combination of urbanization and departure from traditional life styles,
prostitution and spread of sexually transmitted diseases, large public
health campaigns coupled with poor infection control methods, con-
tributed to the development of a perfect environment where HIV gained
a foothold and spread among many African nations and the migrant
Haitian workers in the region many years before its original reports in
the USA and Western Europe.18–19
GLOBAL EPIDEMIOLOGY
The current global estimate for people living with the HIV or AIDS
diagnoses is 34 million.20 Worldwide, there were 2.7 million new HIV
infections in 2010, including 390 000 children, numbers that were 21%
below the number of new infections at the peak of the epidemic in
1997.20 The very encouraging observation of a globally reduced HIV
incidence in 33 countries, 22 of them in Sub-Saharan Africa the region
most affected by the AIDS epidemic, coupled with the wider availabi-
lity of antiretroviral (ARV or ART) therapies and intervention pro-
grams that have especially targeted maternal-child transmission, have
made possible the vision of a world with zero new HIV infections. In
fact, in South and South-East Asia, the estimated new HIV infections
in 2010 was 40% less than at the epidemic’s peak in 1996, and in India,
new HIV infections fell by 56% in the same time period.20 However,
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despite these reductions, certain regions of the world continue to
experience a very high disease burden; in Sub-SaharanAfrica, the adult
HIV prevalence rate is as high as 5.2%; the Caribbean region has the
second highest regional HIV prevalence after Sub-Saharan Africa; in
Eastern Europe and Central Asia, the number of people living with
HIV rose by 250% from 2001 to 2010; and in Latin America, although
the number of newHIV infections has remained stable, the proportion
of women living with HIV is growing.20
Globally, the predominant HIV transmission mode is heterosexual
with two broad patterns identified. One is the generalized epidemic
pattern seen in many Sub-Saharan African countries and the other is
the epidemic seen in the rest of the world that is primarily concen-
trated among populations most at risk.21 The at-risk populations
include men who have sex with men, injecting drug users and sex
workers and their sexual partners.21
HIV STRUCTURE AND LIFE CYCLE
HIV is an enveloped retrovirus that appears spherical in shape with a
number of spikes on its surface.22 The viral core consists of a protein
capsid called p24, two linear RNAmolecules and three enzymes called
reverse transcriptase, integrase and protease. The bilayer viral envel-
ope consists of knob-like spikes, eachmade of an external glycoprotein
gp120 and a transmembrane glycoprotein gp41 and an underlying
layer called the matrix, the protein p17, derived from the virus’ pre-
vious host cell membrane.23–24 The HIV genome consists of three
structural and at least six regulatory genes.25 The structural genes
include Env encoding for the viral envelope proteins gp 120 and gp
41,Gag encoding for thematrix and core proteins p17 and p24 and Pol
encoding for the key viral enzymes protease, reverse transciptase and
integrase.25 The regulatory genes include Tat, Rev, Nef, Vif, Vpr, Vpx
and Vpu.25 After exposure to HIV, successful establishment of infec-
tion involves a series of steps and a complex interaction between the
virus, its regulatory genes and the host immune system. Stages of HIV
infection consist of viral binding and entry, HIV RNA replication and
integration, viral assembly, budding and release of new virions.
HIV entry involves an initial weak interaction between gp120 and
surface molecules such as a4b7 integrin and DC-SIGN followed by a
high affinity interaction with CD4, the primary receptor on CD41 T
cells and also found on the surface of monocytes, dendritic cells and
brain microglia.26–27 HIV–host cell interaction also involves the na-
tural chemokine receptors, CCR5 and CXCR4, which act as coreceptors
for HIV anchorage and entry into the host cell.28 This is accomplished
after the initial CD4 binding and by the HIV gp120 undergoing con-
formational changes that expose the binding sites for the chemokine
receptors.29 The strain of HIV that has an affinity for the CCR5 receptor
is referred to as the R5 strain, the predominant type of HIV in mucosal
transmissions and seen in the early years of infection; this is distinct
from the X4 strain of HIV that primarily uses the CXCR4 coreceptor
and is seen in blood-borne transmissions and later in the course of HIV
diseases.30–31 It has been shown that a genetically variable region of the
gp120 (V3 region) plays an important role in determining the HIV
coreceptor interaction.32–33
After entry into the host cell, HIV may remain dormant for a
long time inside the cell or begin its replication process by pene-
trating the host cell nucleus. Once there, the HIV RNA is reversely
transcribed, mediated by the reverse transcriptase enzyme to form,
first one, and then a second DNA molecule (proviral DNA), which
gets integrated into the host DNA, a process that is mediated by the
integrase enzyme.25 It is this DNA that serves as a blueprint for
making messenger RNAs that are transported outside the host cell
nucleus to help synthesize the new viral genetic material, proteins
and enzymes necessary for forming the new viral particles. In this
process of assembly, the enzyme protease plays a vital role by chop-
ping up long strands of proteins into smaller pieces necessary for
constructing the new mature viral cores. The newly matured HIV
particles are ready to be released by budding from the surface of the
host cell membrane so they can infect another cell and begin the
replication process all over again.
Many of the factors described in the HIV life cycle have been used as
targets for developing antiretroviral drugs. These agents will be dis-
cussed under HIV disease management.
HIV INFECTION AND HOST FACTORS
A small subset of ARV-untreated HIV-infected individuals (about
3%25%) can maintain normal CD4 cell counts for many years
(long-term non-progressors), and an even smaller subset (,1%)
can maintain suppressed viral loads for years (elite controllers).34–35
Several mechanisms have been proposed for these uncommon host
responses to HIV infection and progression. One is the wide genetic
variability in theway people express the kemokine coreceptors on their
HIV target cells. It is this genetic determinant that influences the level
of susceptibility to HIV infection and disease progression—people
without the full coreceptor expression are either immune to HIV
infection or their HIV disease do not progress as rapidly compared
to people who have the full genetic expression. One reported genetic
mutation involves a 32-base pair deletion in CCR5 receptor (CCR5-
D32 allele) that infers resistance in those who are homozygote for the
mutation and slow progression for the heterozygotes, a category that
includes some of the clinically defined long-term non-progressors.36–37
The CCR5-D32 allele is mainly present in Europeans, people from the
Baltic Sea and Central Russia (10% on average), is found with the
lowest frequency in the Mediterranean area, North Africa, Middle
East, Central Asia and is absent in Sub-Saharan Africa, East and
Southeast Asia.38
The long-term non-progressors have a slower course of HIV pro-
gression as defined by CD4 depletion but many ultimately progress to
AIDS.39 In contrast, the elite controllers are at a very low risk for
progression to AIDS, as defined by maintaining a low viral load for
many years and despite absence of treatment.39 For these individuals,
the long-term viral suppression may be due to a number of factor that
include attenuated viral strains, having protective HLA alleles (HLA-
B27 and -B57), strong innate immune responses involving the natural
killer cells and effective viral restriction factors.40 One restriction fac-
tor that has gained a lot of attention is the innate host defensemolecule
‘Apolipoprotein B or APOBEC 3G’, a polypeptide responsible for
amino-acid substitution on newly synthesized viral DNA that func-
tions in interruptingHIV replication.41–42 Another host defensemole-
cule ‘Tetherin’, a membrane protein (CD317) with nonspecific
antiviral properties, can block the envelope protein release.43 Of all
the HIV regulatory genes, Vif has been shown to have the potential to
cripple the APOBEC 3G function and viral Vpu appears to have the
same potential against Tetherin, highlighting the important roles of
the HIV regulatory genes and their products in establishing successful
infection and disease progression.43–44
MECHANISMS AND REGIMENS OF ANTI-RETROVIRAL DRUGS
Remarkable scientific advances of the past three decades have unco-
vered the HIV viral factors andmechanisms that together with a better
understanding of the host immune responses have provided the basis
for developing several potent antiretroviral agents. The currently
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approved and commercially available ARV agents and combination
drugs target specific HIV replicative stages and consist of: (i) nucleos-
ide and nucleotide analog reverse transcriptase inhibitors (NRTI and
NtRTI); (ii) non-nucleoside reverse transcriptase inhibitors (NNRTI);
(iii) protease inhibitors (PI); (iv) fusion inhibitors; (v) integrase
inhibitors (INSTI or integrase strand transfer inhibitors); (vi) entry
inhibitors that currently consist of CCR5 antagonists; and (vii) com-
bination agents.45 The primary aim of anti-HIV treatment is to pro-
vide durable suppression of HIV replication to a level that is below the
detection limits for plasma HIV quantification viral assays.46 Durable
viral suppression results in both, fewer drug-resistant viral variants,
and prevents HIV transmission; resistance occurs through random
mutations during the high rate of HIV replication and mostly because
of poor patient adherence to the medication regimens. There are cur-
rently 36 Food and Drug Administration (FDA)-approved single or
combination ARV drugs on the market and a number of compounds
in line for future FDA approval pending their completion and testing.
Table 1 shows a listing of these antiretroviral agents, their properties
and many of their associated adverse effects.45,47
The most recent recommended combination regimens for treat-
ment-naive patients consist of two NRTIs as the therapeutic backbone
plus one NNRTI (called an NNRTI-based regimen), or a boosted PI
(called a PI-based regimen) or an INSTI (called an INSTI-based regi-
men).45 Usually, an NNRTI-based regimen is used first and in case of
virological or immunological failure, it is changed into a PI-based or an
INSTI-based regimen (Table 2). Virological failure in a patient can
occur because of poor patient drug adherence, drug intolerance/toxicity
or pre-existing (transmitted) drug resistance; it is more likely with
higher HIV RNA levels and/or lower CD4 T-cell counts at baseline,
prior AIDS diagnosis and comorbidities such as active substance abuse
and depression.47 HIV drug-resistance testing is recommended for per-
sons with HIV infection when entering into care and when changing
ARV regimens after virological failure.47 Genotypic testing is recom-
mended as the preferred resistance testing to detect mutations in the
reverse transcriptase and protease genes, while phenotypic assays, mea-
suring the ability of a virus to grow in different concentrations of ARV
drugs, is recommended for persons with known or suspected complex
drug resistance mutation patterns, particularly to PIs.47 Once viro-
logical failure is confirmed, the regimen should be changed as soon
as possible to avoid progressive accumulation of resistance mutations.48
In that case, the regimen of choice will depend on the person’s treat-
ment history and resistance testing and should involve a new mecha-
nistic class.47 Immune-based therapies such as interleukin-2 (IL-2),
IL-7, gene therapies, growth hormone and cyclosporine are not cur-
rently included in the HIV treatment recommendations.47
HIV DISEASE MANAGEMENT
HIV infection leads to a spectrumofmanifestations that progress from
asymptomatic infection to a state of severe immunological suppres-
sion associated with opportunistic fungal, viral and bacterial infec-
tions and malignancies. The immunological suppression seen in HIV
infection, results from a number of immunological defects that
include severe reduction in the CD4-positive T lymphocytes, cytokine
dysregulation and defective innate immune responses.49–52 The mag-
nitude of the immunological suppression determines both indivi-
duals’ initial disease manifestations and also response to treatment.
The initial evaluation of a patient with HIV infection is complex and
should include not only themedical status but alsomany factors in the
social, psychological and psychiatric domains that can influence a per-
son’s ability to adhere to the therapeutic drug regimens. Assessment of
high-risk behaviors, substance abuse, social support, mental illness,
economic factors and housing, medical insurance status and adequacy
of coverage are all important considerations.47 In addition, tests for
sexually transmitted infections, hepatitis C and tuberculosis should
also be a part of the initial and ongoing assessments and, if detected,
their treatment must be included in the person’s comprehensive care
plan.53
One key consideration in HIV disease management is the timing of
antiretroviral therapy (ART) in relationshipwith patient’sHIV disease
state. The current recommendations for initiating ARV treatment is as
early as possible in the course of HIV infection and definitely before
patient’s CD4 count goes below 350 mm23.47 The strong recom-
mendation for initiation of ARV for CD4 counts at values between
350 and 500 mm23 is based on existing evidence from randomized
controlled trials, well-designed non-randomized trials and obser-
vational cohort studies, while the recommendation to start ARVwhen
CD4 is .500 mm23 is based on expert opinion.47 Other factors that
call for earlier therapy include rapidly declining CD4 count, high viral
load, the presence of comorbid conditions and other clinical indica-
tions such as chronic HBV infection and HIV-associated nephropa-
thy.47 In general, CD4 count and plasmaHIV RNA (viral load) should
be measured in all patients at baseline and on a regular basis thereafter
(every 3–4 months), as the CD4 count values help guide ARV treat-
ment initiation and prophylaxis for opportunistic infections, and viral
load is the most important indicator of response to ART.47
Side effects associated with long-term use of ARVs are mostly
related to metabolic complications and cardiovascular disease.
Metabolic complications include hyperglycemia, insulin resistance
and hyperlipidemia (elevations in total cholesterol, low-density lipo-
protein and triglycerides) mostly caused by many of the older formu-
lations of PIs.54 Lipoatrophy or peripheral fat-wasting occurs with the
NRTI use, while visceral fat deposition is seen with PIs and is asso-
ciated with hyperinsulinemia and dyslipidemia.55–56 These metabolic
alterations coupledwith the changes in body composition (with loss of
subcutaneous fat and/or accumulation of visceral fat), inflammation
and the direct effects of the virus on the vasculature increase the risk
for coronary heart disease and require preventivemeasures.57–59 Other
consequences of ARV use include osteoporosis and avascular necrosis
in bones, prostate neoplasia and lethal solid tumors such as non-
Hodgkin lymphoma that are mostly associated with NNRTIs.60–62
Because of the side effects associated with many classes of ARVs, risk
factors for cardiovascular disease, such as hypertension, hyperlipide-
mia, diabetes and tobacco use, should be aggressively managed in all
patients.63–64
As many as 20% of patients who start ARV treatment may experi-
ence specific clinical events associated with immune reconstitution
inflammatory syndrome.65–68 This phenomenon, reported among
people who start treatment when their CD4 counts are very low and
their viral loads are very high, consists of clinical emergence of a prior
subclinical infection or severe recurrence of an old condition.68
Manifestations of immune reconstitution inflammatory syndrome
have been reported to include mostly dermatological lesions such as
anogenital herpes, genital warts, molluscum contagiosum and vari-
cella zoster, as well as other conditions like mycobacterial infections,
hepatitis B and Kaposi’s sarcoma.67–68
HIV PREVENTION STRATEGIES
Global and regional approaches to HIV prevention are focused on eli-
minating perinatal transmission cases though effective prevention of
mother-to-child transmission (PMTCT) initiatives, early identifiation
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Table 1 Major anti-retroviral drugs
Properties
Drug class
NRTIs/NtRTIs NNRTIs PIs INSTIs Fusion inhibitors Entry inhibitors
Multiclass
combinations
Main
formulations
Nucleoside analogs
AZT: zidovudine
(Retrovir)
ddI: didanosine
(Videx)
ddC: zalcitabine
(Hivid)
d4T: stavudine (Zerit)
3TC: lamivudine
(Epivir)
ABC: abacavir
(Ziagen)
FTC: emtricitabine
(Emtriva)
Nucleotide Analogs
TDF: tenofovir
(Viread)
Combinations
AZT/3TC (Combivir)
ABC/3TC (Epzicom)
AZT/ABC/3TC
(Trizivir)
TDF/FTC (Truvada)
First generation
DLV: delaviridine
(Rescriptor)
EFV: efavirenz
(Sustiva)
NVP: nevirapine
(Viramune)
Second generation
ETR: etravirine
(Intelence)
RPV: rilpivirine
(Edurant)
In discovery/trial
Lersivirine (UK-
453061)
First generation
APV: amprenavir
(Agenerase)
SQV: saquinavir
(Invirase)
IDV: indinavir
(Crixivan)
FPV: fosamprenavir
(Lexiva)
RTV: ritonavir
(Norvir)
NFV: nelfinavir
(Viracept)
First generation
TPV: tipranavir
(Aptivus)
DRV: darunavir
(Perzista)
ATZ: atazanavir
(Reyataz)
Combination
Loprinavir/ RTV
(Kaletra)
DRV/low dose RTV
(boosted Prezista)
ATZ/low dose RTV
(boosted Reyetaz)
RAL:
Raltegravir
(Isentress)
EVG:
Elvitegravir
(GS-9137) used
only in combo
in Stribid
In discovery/trial
Dolutegravir
(S/GSK13495
72)
ENF: enfuvirtide
(Fuzeon)
In discovery/trial
Ibalizumab
(TMB-355)
Maraviroc
(Selzentri)
In discovery/trial
Vicriviroc
(SCH 417690)
Cenicriviroc
(TAK-652)
Emtricitabine/
tenofovir/
efavirenz (Atripla)
Emtricitabine/
tenofovir/
rilpivirine (Complera)
Emtricitabine/
tenofovir/elvitegravir/
cobicistat (Stribild)
Advantages Easy dosing schedule
Long half-life
Little food effect
Dual NRT established
as backbone of
combination Tx
Fewer drug
interactions
Low toxicity
Impressive long-
term results
No food effects
Less lipid
abnormalities
Saves PIs for future
use
High genetic
threshold
Useful for treatment-
experienced patients
with NNRTI drug
resistance
Useful for
treatment-
experienced
patients with
multiple drug
resistance
No food effects
Fewer adverse
effects and
interactions
Useful for
treatment-
experienced
patients with
multiple drug
resistance
Useful for adult
patients
infected
with only
CCR5-
tropic HIV-1
Easy to use
Recommended for
treatment-naive
patients
Disadvantages Some members lead
to serious side
effects
Potential for drug
interactions, cross
resistance, and
transmission of
resistance
Screening for HLA-
B*5701 required
for abacavir
Low genetic barrier
for mutation
Cross resistance
Potential for drug
interactions
Complex food
requirements
Cross-resistance is
common and have
severe side effects
CYP3A4 inhibitors
and substrate
Drug interaction
Side effects
Lower genetic
barrier for
mutations than
PIs
Effectiveness in
treatment-
naive patients
still being
studied
Not
recommended
in patients with
dual/mixed or
CXCR4-
tropic HIV-1
Requires viral
tropism assay
Bronchitis
Drug interactions
Rilpivirine has higher
rate of virological
failure if HIV-1 RNA
.100 000
copies?mL21
Major side
effects
Peripheral neuropathy
Myopathy and
myositis
Cardiomyopathy
Lactic acidosis
Hepatic steatosis
(adiposis)
Lipodystrophy
Pancreatitis
Bone marrow
suppression
Hepatic and renal
toxicity
Neuropsychiatric
effects
Drug–drug
interactions
Stevens–Johnson
syndrome
Insulin resistance
Dyslipidemia
Hepatotoxicity
Osteonecrosis and
osteoporosis
Drug–drug interactions
Possible increased
bleeding risk in
hemophiliacs
Depression
Suicidal
tendencies
Myopathy and
rhabdomyolysis
Reported Stevens–
Johnson
syndrome and
toxic epidermal
necrolysis
Risk of kidney
dysfunction
Injection-site
reactions
Hypersensitivity
reaction
Increased risk
of bacterial
pneumonia
Heaptotoxicity
Cardiovascular
events
Bladder irritation
Upper respiratory
tract infection
Hepatic and
renal toxicity
Lactic acidosis
With HBV co-infection,
discontinuation can
lead to severe acute
HB exacerbations
Neuropsychiatric
effects
Major drug
interactions
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of infections through testing and linkage to care programs and protect-
ing uninfected high-risk individuals against HIV transmission.
Perinatal HIV transmission
In high-income countries, identification of HIV-infected pregnant
women and the use of ARV prophylaxis have been very successful in
reducing the number of mother-to-child transmissions. For instance,
in the United States, the number of perinatal transmissions dropped
from 945 cases in 1992 to 48 cases in 2004.69 However, in low- to
middle-income countries, nearly half of all HIV-positive pregnant
women may not be receiving any intervention and remain at risk for
disease progression and transmission to their unborn child.70 The
global goal in PMTCT has recently been updated to include: (i) pro-
vision of lifelong ART for HIV-infected women who are in need of
treatment (CD4 count ,350 mm23) in order to protect their own
health and also to prevent transmission to their child; and (ii) short-
term combination ARV prophylaxis for HIV-infected women who are
not in need of treatment (CD4 count.350mm23) in order to prevent
transmission of HIV to their child during pregnancy, delivery and
breastfeeding.71–73
Male circumcision
Clinical trials in Kenya, South Africa and Uganda indicate that vol-
untary medical male circumcision reduces the risk of female-to-male
sexual transmission by about 60%.20 To maximize the benefits of
this prevention strategy, men of all ages must be targeted for me-
dical male circumcision. It is estimated that in Eastern and
Southern Africa, 20 million males need to be circumcised and if
this goal is achieved, it will avert approximately 3.4 million new
HIV infections by 2015.20
Treatment as prevention
Antiretrovairal treatment not only averts AIDS-related complications
and deaths by preventing HIV disease progression, also reduces the
Properties
Drug class
NRTIs/NtRTIs NNRTIs PIs INSTIs Fusion inhibitors Entry inhibitors
Multiclass
combinations
Common side
effects
Nausea, vomiting,
abdominal pain,
diarrhea, loss of
appetite, lethargy,
muscle weakness,
insomnia,
headache,
dizziness
Nausea, vomiting,
diarrhea,
insomnia,
unusual or vivid
dreams, dizziness,
rash
Nausea, vomiting,
diarrhea, rash,
headache
Nausea, diarrhea,
fever, headache
Fatigue,
numbness in
feet or legs,
dizziness,
insomnia
Nausea, cough,
fever,
dizziness,
headache,
bloating and
distention
Diarrhea, nausea,
fatigue, headache,
dizziness,
depression,
insomnia, abnormal
dreams and rash
NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside analog reverse transcriptase inhibitors; NtRTIs, nucleotide analog reverse transcriptase
inhibitors; PI, protease inhibitors.
Table1 continue
Table 2 Initial combination regimens for the antiretroviral naive patient
Regimens Chemical names Common trade names
Preferred regimen
NNRTI-based regimens
NRTI/NRTI/ NNRTI tenofovir/emtrcitabine/efavirenz Atripla
PI-based regimens
NRTI/NRTI 1 boosted PI tenofovir/emtrcitabine 1 ritonavir/atazavir Truvada 1 Boosted Reyetaz
NRTI/NRTI 1 boosted PI tenofovir/emtrcitabine 1 ritonavir/darunavir Truvada 1 Boosted Prezista
INSTI-based regimen
NRTI/NRTI 1 INSTI tenofovir/emtrcitabine 1 raltegravir Truvada 1 Isentress
Alternative regimen
NNRTI-based regimens
NRTI/NRTI 1 NNRTI emtricitabine/tenofovir/rilpivirine
abacavir/lamivudine 1 efavirenz
abacavir/lamivudine 1 rilpivirine
Complera
Epzicom 1 Sustiva
Epzicom 1 Edurant
PI-basedrRegimens
NRTI/NRTI 1 boosted PI abacavir/lamivudine 1 ritonavir/atazavir
abacavir/lamivudine 1 ritonavir/darunavir
abacavir/lamivudine or tenofovir/emtrcitabine
1 ritonavir/fosamprenavir
abacavir/lamivudine or tenofovir/emtrcitabine
1 ritonavir/loprinavir
Epzicom 1 Boosted Reyetaz
Epzicom 1 Boosted Prezista
Epzicom or Truvada 1 Boosted Lexiva
Epzicom or Truvada 1 Kaltetra
INSTI-based regimen
NRTI/NRTI 1 INSTI abacavir/lamivudine 1 raltegravir
tenofovir/emtrcitabine/cobistat/elvitegravir
Epzicom 1 Isentress
Stribid
NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside analog reverse transcriptase inhibitors; NtRTIs, nucleotide analog reverse transcriptase
inhibitors; PI, protease inhibitors.
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risk of HIV transmission by lowering individuals’ viral loads.74 For
this reason, universal access to treatment has been amajor focus of the
HIV intervention programs throughout the world. Themost dramatic
increases in antiretroviral therapy coverage have occurred in Sub-
Saharan Africa where universal access to treatment (defined as 80%,
or greater coverage) has been achieved in Botswana, Namibia and
Rwanda, while in countries such as Latvia, Nepal and Sudan, this
percentage is still at below 19%.20
Universal HIV screening
A significant percentage of individuals who are infected with HIV
are unaware of their HIV infection. A national study in Kenya
showed only 16% of HIV-infected adults knew that they were
infected, while in the United States, this percentage is currently
about 20%.75–76 HIV screening is an effective prevention tool
because it can help with early identification and treatment of those
infected and also because the newly diagnosed are less likely to
engage in unprotected sex and with multiple partners.20 Universal
HIV screening was implemented in the United States in 2006; how-
ever, because fear of social stigma is still a key prohibitive factor for
universal HIV screening in many regions of the world, in the 2012
Joint United Nations Programme on HIV/AIDS report, the imple-
mentation of home HIV testing is identified as a significant HIV
prevention strategy for the next decade.20
Non-occupational post-exposure prophylaxis and pre-exposure
prophylaxis
Recent approaches to protecting individuals who are at risk for HIV
infection target sexually transmitted infections and involve pre-
and post-exposure prophylaxis. In the United States, based on the
recommendations issued by the US Centers for Disease Control,
individuals who report a non-occupational exposure to infectious
body fluids with an HIV-infected source or a high-risk exposure,
should receive a 28-day course of ART as prophylaxis against HIV
infection (non-occupational post-exposure prophylaxis) and the
daily use of tenofovir/emtricitabine (Truvada) is recommended as
pre-exposure prophylaxis of HIV-uninfected high-risk gay men and
partners of gay and heterosexual serodiscordant couples.77–79 The
rationale for these recommendations are provided by encouraging
results from clinical trials conducted in Botswana, Zambia and
South Africa.80–81
A recent mathematical model showed that a combination interven-
tion program of HIV that consists of screening, early ART, male cir-
cumcision, the use of microbicides and pre-exposure prophylaxis can
avert 62% of HIV infections, while only two interventions of HIV
screening and early ART can reduce infections by 34%.82
NEW INTERVENTION STRATEGIES
The new intervention methods in HIV management and prevention
target gene-based therapies, interference with HIV receptor and
coreceptor interactions, the use of effective innate immune host
factors, eliminating the HIV cellular reservoirs, and reducing the
role chronic inflammation in HIV progression. These approaches
are explored for their potential in enhancing the conventional HIV
medical treatments and also in developing an effective HIV vaccine
in the near future.
Gene-based therapies
In 2009, a single case of HIV cure in Germany received a great deal of
attention by the scientific community and themassmedia and became
known as the ‘Berlin patient’.83 This was an HIV seropositive male
who after receiving an allogeneic bone marrow graft carrying the
homozygous CCR5-D32 alleles for treatment of acute leukemia
remained free of HIV viral rebound for up to twenty months after
his bone marrow transplant and discontinuation of ART, a status that
has remained stable until now. The serendipitous success of this case
opened the door for targeted gene therapy and the use of autologous
transplantation of genetically modified CD4-positive T cells or even
stem cells which, by the way, still require myeloablation as a major
therapeutic challenge.84 Another potential approach in gene therapy
involves the use of small RNAs, such as siRNAs, to interfere with post-
transcriptional gene silencing and interference withHIV replication.85
The major challenge with RNA-based therapies lies with their poten-
tial in inducing an endogenous effect and in-vivo toxicity.84
HIV receptor, coreceptor inhibition
CCR5 antagonists are the new class of antiretroviral agents that are
targeted to HIV entry into the host cell. They include maraviroc,
available commercially, and vicriviroc and centriviroc that are in clin-
ical testing.47,86–87 A viral assay (Trofile Assay; Monogram Biosciences
San Francisco, CA, USA) has been developed to determine the pro-
portion of the HIV viruses in an individual with the R5 strain.88 By
using information obtained from this assay, the CCR5 antagonist
maraviroc has entered clinical use for blocking HIV entry in indivi-
duals who are primarily infected with the R5 strain. Among other
drugs targeting HIV entry, are several monoclonal antibody formulas
against CCR5 and ibalizumab, the monoclonal antibody against the
V3 loop of GP 120, that are still in development and testing.89–92
Enhancing the innate host immune factors
New approaches to ARV development include targeting innate
immune responses shown to be effective in HIV suppression. Some
of the targets include ‘APOBEC 3G’ that interferes with viral DNA
synthesis, ‘Tetherin’ that blocks viral release and TRIMa that destabi-
lizes the HIV capsid and interferes with reverse transcription.93–97
Another candidate target is ‘LEDGF/p75’, an integrase enzyme cofac-
tor, whose antagonists are being studied for their ability to suppress
HIV replication.98 Other possible ARVmechanisms involve the endo-
genously secreted antimicrobial peptides such as defensins, lactofer-
rins, secretory leukocyte protease inhibitor and Trappin-2/Elafin that
all have shown to possess strong anti-HIV properties.95–96
Elimination of the HIV reservoirs and chronic immune activation
Effective antiretroviral therapy leads to plasma HIV-RNA levels that
are below the detection limit of the commonly used viral assays.
However, for most individuals, a residual low-level viremia can be
detected by ultrasensitive assays and the interruption of treatment
results in a rapid viral rebound even after long-term ART use; these
factors make HIV eradication from all the viral reservoirs a major
challenge in its medical management.99 While plasma HIV-RNA is a
virological marker for HIV disease progression, the HIV-DNA levels
in peripheral blood monononuclear cells reflect the magnitude of the
intracellular HIV reservoirs that also include the latently infected
memory T cells. Although the exact dynamic of these viral reservoirs
is not fully understood, the reactivation of the integratedHIV from the
dormant cells is responsible for the viral rebound after discontinuation
of ART, whereas ongoing viral replication in these cells may explain
the sustained low level viremia among patients receiving ART.100
Treatment strategies aiming to activate the latent cells and making
them more sensitive to host immune mechanisms have included the
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use of cytokines like IL-2 and IL-7, raltegravir and CCR5 antagonists,
all in addition to the use of ART.101–103
Chronic immune activation with polyclonal B-cell activation,
increased T-cell turnover and increased serum levels of pro-inflammat-
ory cytokines and chemokines is a common feature of chronic HIV
infection.104 The sustained immune activation not only leads to pro-
gressive loss of CD4 T cells and their depletion, but also promotes
thrombosis and other aging-related diseases; this can be demonstrated
by sustained levels of inflammatory markers such as IL-6 and the coagu-
lation marker, the d-dimer, in plasma.105–106 In fact, the gut-associated
lymphoid tissue is a prime target early in the course of HIV infection and
remains a chronically infected tissue and a main reservoir for the dorm-
ant T cells in the course of HIV infection and progression.107 Two
treatment approaches have included the class of cox-2 inhibitors and
the lipid-lowering agent atorvastatin in conjunction with ART.108–109
HIV vaccine
The extraordinary diversity of HIV-1 throughout the world, its capacity
to evade host immune responses, a lack of broadly reactive antibody
response in most infections and the early establishment of latent viral
reservoirs have been major obstacles for those in search of an effective
HIV vaccine.110 Over the past two decades, two candidate vaccines have
reached clinical efficacy studies, one used a monomeric HIV-1 Env
gp120 protein aiming to induce Env-specific humoral immune res-
ponses111–112 and the other used a recombinant adenovirus serotype
vector expressing the main HIV-1 genes (Gag, Pol and Nef) to elicit
HIV-1-specific cellular immune responses.113 Unfortunately, these
approaches were shown ineffective in protecting against HIV infection
as the rapid mutations in HIV envelope glycoproteins rendered the Env-
specific antibodies ineffective and the cellular immune responses did not
provide adequate immunity against infection.114–115 More recently, the
identification of a broadly reactive neutralizing antibody activity in elite
controllers116 has redirected the HIV vaccine discovery efforts to the
potential use of these natural antibodies as templates for developing a
broadly neutralizing antibody-based vaccine in the near future.117
SUMMARY
Major scientific advances of the past 30 years have paved the way for
therapeutic agents that can effectively suppress HIV viral replication.
Amajor challenge in HIV eradication is the presence of HIV reservoirs
that persist, despite effective treatments and optimal medication
adherence and require lifelong treatment for those infected. Future
treatments will focus on targeting these reservoirs and also on redu-
cing the role of chronic inflammatory conditions and comorbidities
that promote HIV disease progression. Efforts in developing an effec-
tive vaccine are promising and, if the current trends in developping
new HIV treatment and prevention approaches continue, the global
target of zero new infections may soon be realized.
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